| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a70b05f3bdf7f6e9aaf7a41ac3aacdc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-397
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-397 |
| filingDate |
2005-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7273e3ad5f35c91f5b2de088fd650043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b9d62a060ff07d4a0cb5618751583d1 |
| publicationDate |
2007-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1819326-A1 |
| titleOfInvention |
Dosage regimen of an s1p receptor agonist |
| abstract |
S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial 3 to 6 days of treatment the daily dosage is raised so that in total the R-fold (R being the accumulation factor) standard daily dosage is administered and thereafter continued at the standard daily dosage or at a daily dosage lower than the standard daily dosage. |
| priorityDate |
2004-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |